Iron deficiency in heart failure: Introduction

Leave a comment
Click any image to enlarge
Authors:
Sponsorship Statement:

This supplement was fully funded by an unrestricted grant from Vifor Pharma UK Limited. The content of the articles was independently developed by the authors and according to a brief agreed between Vifor Pharma UK and the BJC. Vifor Pharma reviewed the final version of each article for Code Compliance only. Prescribing information for Ferinject ▼ (ferric carboxymaltose) can be found here.

Job code: UK-FCM-2100010
Date of preparation: January 2021

This supplement marks 10 years of experience with intravenous irons in the treatment of iron deficiency in heart failure. It reviews and discusses:

  • – the epidemiology, mechanisms and guidelines for treatment of iron deficiency in heart failure
  • – the treatment of iron deficiency in UK patients with heart failure and how to set up an intravenous (IV) iron therapy service
  • – iron therapies, particularly the latest IV irons, including their efficacy, tolerability, side effects and differences
  • – the patient’s experience showing the beneficial effects of IV irons on quality of life and symptoms.

Contents

Prevalence, causes, diagnosis and guidelines for treatment
Mohamed Eltayeb, Vishnu Ashok, Iain Squire

United Kingdom treatment of iron deficiency in heart failure: are we missing opportunities?
Chun Shing Kwok, Sarah McDermott, Sadie Bennett, Simon Duckett

Intravenous iron therapies and their differences
Paul Foley

Iron deficiency – the invisible comorbidity in HF: prioritising QoL as a target for treatment
Jacquelyn Hooper, Nick Hartshorne-Evans, Colin Cunnington, Fozia Zahir Ahmed

Conclusions
Iain Squire

Disclaimer:

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The editors/authors/contributors and the publishers Medinews (Cardiology) Ltd have taken care to ensure that the information given in this text is accurate and up to date at the time of publication.

Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice. Medinews (Cardiology) Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.

The opinions, data and statements that appear are those of the contributors. The publishers, editors, and members of the editorial board do not necessarily share the views expressed herein. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the publisher, editors, the editorial board or their agents or employees is accepted for the consequences of any inaccurate or misleading information.

© Medinews (Cardiology) Ltd 2021. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publishers, Medinews (Cardiology) Ltd. It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT